Prognostic Value of Poorly Differentiated Clusters in Invasive Breast Cancer

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2014 Oct 13

PMID 25306264

Citations 15

Authors

Ying Sun

Fenli Liang

Wei Cao

Kai Wang

Jianjun He

Hongyan Wang

Yili Wang

Affiliations

Soon will be listed here.

Abstract

Background: Our study aimed to assess the prognostic value of poorly differentiated clusters (PDCs) in invasive breast cancer.

Methods: A total of 146 cases of operable invasive ductal carcinoma that was not otherwise specified (IDC-NOS), from 2002 to 2009, were pathologically reviewed. Cancer clusters with five or more cancer cells and lacking gland-like structures were counted from a field containing maximum clusters in H & E slides under a×20 objective lens (0.950 mm2 field of vision).

Results: Tumors with <5, 5 to 9, and ≥10 clusters were graded as G1, G2, and G3, respectively (n=41, 60, and 45 tumors, respectively). An interobserver test showed good reproducibility, with a Cohen's kappa coefficient of 0.739. The PDC grade was significantly associated with N stage (P<0.001), lymphovascular invasion (P=0.007), tumor budding grade (P<0.001), relapse rate (P<0.001), and death rate (P<0.001). Survival analyses revealed that the PDC grade was a significant prognostic factor for disease-free survival (hazard ratio 3.811; P<0.001) and overall survival (hazard ratio 3.730; P=0.001), independent of T stage, N stage, or tumor budding grade.

Conclusions: The PDC grade is an independent prognostic factor of IDC-NOS. Considering the simplicity and availability of this method relative to conventional clinical pathology, PDCs may serve as a novel prognostic histological characteristic in IDC-NOS.

Citing Articles

The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.

Xu H, Wei D Biomol Biomed. 2024; 24(6):1546-1558.

PMID: 39319896 PMC: 11496871. DOI: 10.17305/bb.2024.11103.

High charge of cerebroid nests in nodular melanomas predicts tumor aggressiveness and high mutational tumoral burden: a pilot study.

Caramaschi S, Mangogna A, Bertoni L, Manfredini M, Farnetani F, Parente P Front Oncol. 2024; 14:1336895.

PMID: 39099686 PMC: 11294109. DOI: 10.3389/fonc.2024.1336895.

Tumor budding - a potential biomarker in low grade salivary gland carcinomas?.

Burkhardt V, Kayser G, Villing T, Becker C Front Oncol. 2024; 14:1410264.

PMID: 38983934 PMC: 11231199. DOI: 10.3389/fonc.2024.1410264.

Grades of Poorly Differentiated Clusters are Associated with Lymph Node and the Tumour, Node and Metastasis Stages in Colorectal Carcinoma.

Kerisnon Krishnan T, Mohtarrudin N, Wan Yaacob W, Hussin H Malays J Med Sci. 2024; 30(6):70-78.

PMID: 38239248 PMC: 10793141. DOI: 10.21315/mjms2023.30.6.8.

Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.

Rustamadji P, Wiyarta E, Bethania K Iran J Pathol. 2022; 17(4):480-490.

PMID: 36532641 PMC: 9745758. DOI: 10.30699/IJP.2022.551244.2866.

References

Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass J . A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology. 2005; 47(1):25-31. DOI: 10.1111/j.1365-2559.2005.02162.x. View

Giger O, Comtesse S, Lugli A, Zlobec I, Kurrer M . Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol. 2012; 25(7):1048-53. DOI: 10.1038/modpathol.2012.56. View

Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T . Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2007; 10(1):41-7. DOI: 10.1111/j.1463-1318.2007.01240.x. View

Rampaul R, Pinder S, Elston C, Ellis I . Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol. 2001; 27(3):229-38. DOI: 10.1053/ejso.2001.1114. View

Gujam F, Going J, Edwards J, Mohammed Z, McMillan D . The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol. 2013; 89(2):231-41. DOI: 10.1016/j.critrevonc.2013.08.014. View

Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22. DOI: 10.1007/978-0-387-74039-3_1. View

Freedman L, EDWARDS D, McConnell E, Downham D . Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer. 1979; 40(1):44-55. PMC: 2009958. DOI: 10.1038/bjc.1979.139. View

Knorr K, Hilsenbeck S, Wenger C, Pounds G, Oldaker T, Vendely P . Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat. 1992; 22(3):251-62. DOI: 10.1007/BF01840838. View

Hase K, Shatney C, Johnson D, Trollope M, Vierra M . Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993; 36(7):627-35. DOI: 10.1007/BF02238588. View

10.

Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masuda D . Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep. 2012; 6(5):937-43. PMC: 3493086. DOI: 10.3892/mmr.2012.1048. View

11.

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

12.

Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z . The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013; 209(5):269-75. DOI: 10.1016/j.prp.2013.01.009. View

13.

Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K . New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 2012; 36(2):193-201. DOI: 10.1097/PAS.0b013e318235edee. View

14.

Prall F . Tumour budding in colorectal carcinoma. Histopathology. 2007; 50(1):151-62. DOI: 10.1111/j.1365-2559.2006.02551.x. View

15.

Masood S . Raising the bar: a plea for standardization and quality improvement in the practice of breast pathology. Breast J. 2006; 12(5):409-12. DOI: 10.1111/j.1075-122X.2006.00337.x. View

16.

Boros M, Marian C, Moldovan C, Stolnicu S . Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas. Pathol Res Pract. 2012; 208(10):604-9. DOI: 10.1016/j.prp.2012.07.005. View

17.

Jung S, Rosenzweig M, Sereika S, Linkov F, Brufsky A, Weissfeld J . Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2011; 23(1):103-12. DOI: 10.1007/s10552-011-9859-8. View

18.

Alderson M, Hamlin I, Staunton M . The relative significance of prognostic factors in breast carcinoma. Br J Cancer. 1971; 25(4):646-56. PMC: 2008856. DOI: 10.1038/bjc.1971.80. View

19.

Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A . Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer. 2012; 49(5):1032-9. DOI: 10.1016/j.ejca.2012.10.022. View

20.

Imperato P, Waisman J, Wallen M, Llewellyn C, Pryor V . Improvements in breast cancer pathology practices among medicare patients undergoing unilateral extended simple mastectomy. Am J Med Qual. 2003; 18(4):164-70. DOI: 10.1177/106286060301800406. View